Compare SPH & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPH | ORIC |
|---|---|---|
| Founded | 1945 | 2014 |
| Country | United States | United States |
| Employees | 3341 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2020 |
| Metric | SPH | ORIC |
|---|---|---|
| Price | $20.38 | $12.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 89.4K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 42.11 | 19.67 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,432,518,000.00 | N/A |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $29.72 | ★ N/A |
| Revenue Growth | ★ 7.94 | N/A |
| 52 Week Low | $17.30 | $3.90 |
| 52 Week High | $21.72 | $14.93 |
| Indicator | SPH | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 52.17 |
| Support Level | $20.00 | $11.37 |
| Resistance Level | $20.70 | $12.60 |
| Average True Range (ATR) | 0.40 | 0.79 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 20.71 | 66.74 |
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.